Immunotherapy IRC @fredhutch

The Immunotherapy Integrated Research Center accelerates discovery by promoting cross-disciplinary and cross-divisional collaboration @fredhutch.

[Immunotherapy IRC @fredhutch @FH_IRC]

Researchers optimized a method to isolate nuclei from flash‑frozen mouse colon tissue for single‑nuclei RNA sequencing using  Miltennyi’s lysis buffer and Octo-dissociator with chillers. The protocol improved nuclei RNA quality and counting prior to fixing nuclei for the 10x. FLEX- Multiplex protocol, supporting high‑quality, cost-effective molecular profiling when other single‑cell methods aren’t possible. @HutchInnovation https://t.co/5cK7k8BZkM

[Aaron Ring @aaronmring]

Autoantibodies cause autoimmune disease, shape infection outcomes, and alter cancer immunotherapy. But what role might they play in neuropsychiatric disease? In our new preprint, Katlyn Nemani and @JillianRJaycox take on this question in schizophrenia. 🧵
https://t.co/lmL4sx7QSz

[Aaron Ring @aaronmring]

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too?

That’s the question @yile_dai looked to answer in his thesis work, out today in @Nature! 🧵below

https://t.co/VgTByRKRCX

[Immunotherapy IRC @fredhutch @FH_IRC]

https://t.co/y9JwNWhqI6 In 4,258 patients, donor age affected outcomes differently depending on donor type. @fredhutch researchers & collaborators found while younger family donors showed rising risk once donors were ~38, matched unrelated donors stayed low‑risk until ~50 with better overall survival, allowing for more personalized donor choices.

[Immunotherapy IRC @fredhutch @FH_IRC]

https://t.co/PE42SewseP via @fredhutch

[Immunotherapy IRC @fredhutch @FH_IRC]

CAR‑T saves lives but can disrupt humoral immunity. New data show CD19/20 CAR‑T recipients often lack protective antibodies to ~1/3 of vaccine‑preventable pathogens for up to a year, with even larger gaps after BCMA CAR‑T. Re‑vaccination helps—especially in patients with higher B‑cell counts. @fredhutch
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response | Nature Communications

[Immunotherapy IRC @fredhutch @FH_IRC]

PhD (or equivalent) students within 2 years of graduation or who have graduated in the last year - Apply to visit with faculty at @FredHutch and hear about opportunities at this world-renowned institution. Food, lodging and travel covered! Apply by June 1: https://t.co/AGzR7hRzQO

[Immunotherapy IRC @fredhutch @FH_IRC]

Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries | New England Journal of Medicine https://t.co/apCODBoE8b

[Immunotherapy IRC @fredhutch @FH_IRC]

Tyrosine kinase inhibitor drugs can be highly effective against chronic myeloid leukemia, but access to these life-saving drugs and necessary clinical support is limited in low- and middle-income countries. The authors report that these barriers can be overcome to enable long-lasting remissions in resource-limited settings. @fredhutch @JerryRadich Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries | New England Journal of Medicine

[Immunotherapy IRC @fredhutch @FH_IRC]

https://t.co/hrJlepUUi3

[Immunotherapy IRC @fredhutch @FH_IRC]

Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma.  @Fredhutch Matthias Stephan Lab discovery: new mRNA-based foam coats the esophagus, delivering apoptosis-inducing therapy directly to tumors. In vitro, it showed 110× higher tumor regression than suspension and boosted radiotherapy effects—offering hope for home-based, less disruptive treatment. Matthias Stephan to present findings at Digestive Disease Week: https://t.co/lR5t4DNIKU

[Immunotherapy IRC @fredhutch @FH_IRC]

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation https://t.co/aQDMyl64qX

[Immunotherapy IRC @fredhutch @FH_IRC]

@fredhutch investigators found that young ALL patients in third or later remission were more likely than those in second remission to experience transplant-associated mortality after transplant, highlighting the critical need for new strategies to reduce side-effects in patients in third remission or beyond and to strongly consider transplantation in second remission." https://t.co/mqUzKbE9UU
Transplantation of donor-derived blood-forming stem cells is commonly used to treat patients with recurrent acute lymphoblastic leukemia (ALL), reducing relapse risk but sometimes causing significant toxicities.

[Immunotherapy IRC @fredhutch @FH_IRC]

@fredhutch investigators found that young ALL patients in third or later remission were more likely than those in second remission to experience transplant-associated mortality after transplant, highlighting the critical need for new strategies to reduce side-effects in patients in third remission or beyond and to strongly consider transplantation in second remission. https://t.co/mqUzKbE9UU
Transplantation of donor-derived blood-forming stem cells is commonly used to treat patients with recurrent acute lymphoblastic leukemia (ALL), reducing relapse risk but sometimes causing significant toxicities.

[Yapeng Su @SuYapeng]

"Huge thanks to an amazing team, mentors, and collaborators at @fredhutch @FH_IRC and globally
📄 Nature: “The ubiquitin ligase KLHL6 drives resistance to CD8�� T cell dysfunction”
🔗 (https://t.co/BUevIoU2HO)

[Immunotherapy IRC @fredhutch @FH_IRC]

@HutchInnovation @fredhutch Evaluating the practical aspects and performance of commercial single-cell RNA sequencing technologies https://t.co/KzlKbHNHhN

[Immunotherapy IRC @fredhutch @FH_IRC]

@hutchinnovation, @fredhutch Evaluating the practical aspects and performance of commercial single-cell RNA sequencing technologies https://t.co/KzlKbHNHhN